Cover Image
Market Research Report

Patient Derived Xenograft/PDX Models Market by Type (Mouse & Rat), Tumor Type (Gastrointestinal, Gynecological, Respiratory), Application (Pre-Clinical Drug Development & Biomarker Analysis), End User (Pharma & Biotech, CRO) - Global Forecast to 2022

Published by MarketsandMarkets Product code 556899
Published Content info 155 Pages
Delivery time: 1-2 business days
Price
Back to Top
Patient Derived Xenograft/PDX Models Market by Type (Mouse & Rat), Tumor Type (Gastrointestinal, Gynecological, Respiratory), Application (Pre-Clinical Drug Development & Biomarker Analysis), End User (Pharma & Biotech, CRO) - Global Forecast to 2022
Published: September 14, 2017 Content info: 155 Pages
Description

"PDX models market is projected to grow at a CAGR of 16.7%"

The global PDX models market is estimated to grow at a CAGR of 16.7% from 2017 to 2022, to reach USD 167.6 million. The key factors driving the growth of the overall PDX models market include the growing demand for personalized medicine, continuous support for cancer research from the public as well as private sectors, and growth in the number of R&D activities in the pharmaceutical industry. However, the high cost of personalized PDX models and stringent guidelines regarding the ethical use of animals in cancer research are expected to restrain the growth of this market during the forecast period.

"The respiratory tumor models segment is projected to grow at the highest CAGR during the forecast period"

Based on tumor type, the PDX models market is segmented into gastrointestinal tumor models, gynecological tumor models, respiratory tumor models, urological tumor models, hematological tumor models, and other tumor models such as head & neck cancer, sarcoma, and melanoma. During the forecast period, the respiratory tumor models segment is expected to register the highest CAGR. Growth in this segment is mainly driven by the increasing focus of market players on generating lung cancer PDX models, which could lead to a breakthrough in lung cancer treatment, as lung cancer is the leading cause of cancer-related deaths across the globe.

"Asia Pacific to witness the highest growth during the forecast period"

Asia Pacific is expected to grow at the highest CAGR in the global PDX models market during the forecast period of 2017-2022. Strong research expenditure and the well-structured CRO industry in China, growth in biomedical & medical research in Japan, rising pharmaceutical R&D expenditure in India, and rising translational and biomedical research in Singapore are expected to drive the market growth during the forecast period.

Break of primary participants was as mentioned below:

  • By Company Type - Tier 1-55%, Tier 25%, and Tier 20%
  • By Designation - C-level-43%, Director Level-32%, Others-25%
  • By Region - North America-38%, Europe-23%, Asia-Pacific-29%, RoW-10%

The various players in the PDX models market include Crown Bioscience Inc. (US), WuXi AppTec (China), Champions Oncology, Inc. (US), The Jackson Laboratory (US), ONCODESIGN (France), Charles River Laboratories International, Inc. (US), EPO Berlin-Buch GmBH (Germany), Shanghai LIDE Biotech Co., Ltd. (China), Xentech (France), Horizon Discovery Group PLC (UK), Urolead (France), and Explora BioLabs (US).

Research Coverage:

The report analyzes the PDX models market and aims at estimating the market size and the future growth potential of this market based on various segments such as type, tumor type, application, end user, and region. The report also includes competitive analysis of the key players in this market along with their company profiles, product and service offerings, recent developments, and key market strategies.

Reasons to Buy the Report:

The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a greater share. Firms purchasing the report could use any one or a combination of the below-mentioned five strategies.

This report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on product and service portfolios offered by the top players in the global PDX models market
  • Service Enhancement/Innovation: Detailed insights on upcoming trends and service launches in the global PDX models market
  • Market Development: Comprehensive information about the lucrative emerging markets by type, tumor type, application, end user, and region
  • Market Diversification: Exhaustive information about new services or service enhancements, growing geographies, recent developments, and investments in the global PDX models market
  • Competitive Assessment: In-depth assessment of growth strategies, products, and services of leading players in the market
Table of Contents
Product Code: BT 5576

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. MARKET SCOPE
    • 1.3.1. MARKETS COVERED
    • 1.3.2. YEARS CONSIDERED FOR THE STUDY
  • 1.4. CURRENCY
  • 1.5. LIMITATIONS
  • 1.6. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. RESEARCH METHODOLOGY STEPS
  • 2.2. SECONDARY AND PRIMARY RESEARCH METHODOLOGY
    • 2.2.1. SECONDARY RESEARCH
      • 2.2.1.1. Key data from secondary sources
    • 2.2.2. PRIMARY RESEARCH
      • 2.2.2.1. Key industry insights
      • 2.2.2.2. Key data from primary sources
      • 2.2.2.3. Key insights from primary sources
  • 2.3. MARKET SIZE ESTIMATION METHODOLOGY
  • 2.4. MARKET FORECAST METHODOLOGY
  • 2.5. MARKET DATA VALIDATION AND TRIANGULATION
  • 2.6. ASSUMPTIONS

3. EXECUTIVE SUMMARY

4. PREMIUM INSIGHTS

  • 4.1. PDX MODELS MARKET OVERVIEW
  • 4.2. REGIONAL ANALYSIS: GLOBAL PDX MODELS MARKET, BY END USER
  • 4.3. GLOBAL PDX MODELS MARKET, BY TUMOR TYPE, 2017 & 2022
  • 4.4. REGIONAL SNAPSHOT OF THE GLOBAL PDX MODELS MARKET

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET DYNAMICS
    • 5.2.1. DRIVERS
      • 5.2.1.1. Growing demand for personalized medicine
      • 5.2.1.2. Continuous support for cancer research from public as well as private sector
      • 5.2.1.3. Growth in the number of pharmaceutical R&D activities
    • 5.2.2. RESTRAINTS
      • 5.2.2.1. High cost of personalized PDX models
      • 5.2.2.2. Stringent guidelines for the use of animal models in cancer research
    • 5.2.3. OPPORTUNITY
      • 5.2.3.1. Rising demand for humanized PDX models
    • 5.2.4. CHALLENGE
      • 5.2.4.1. Limitations of PDX models

6. PDX MODELS MARKET, BY TYPE

  • 6.1. INTRODUCTION
  • 6.2. MICE MODELS
  • 6.3. RAT MODELS

7. PDX MODELS MARKET, BY TUMOR TYPE

  • 7.1. INTRODUCTION
  • 7.2. GASTROINTESTINAL TUMOR MODELS
  • 7.3. GYNECOLOGICAL TUMOR MODELS
  • 7.4. RESPIRATORY TUMOR MODELS
  • 7.5. UROLOGICAL TUMOR MODELS
  • 7.6. HEMATOLOGICAL TUMOR MODELS
  • 7.7. OTHER TUMOR MODELS

8. PDX MODELS MARKET, BY APPLICATION

  • 8.1. INTRODUCTION
  • 8.2. PRECLINICAL DRUG DEVELOPMENT AND BASIC CANCER RESEARCH
  • 8.3. BIOMARKER ANALYSIS

9. PDX MODELS MARKET, BY END USER

  • 9.1. INTRODUCTION
  • 9.2. PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 9.3. CONTRACT RESEARCH ORGANIZATIONS
  • 9.4. ACADEMIC & RESEARCH INSTITUTIONS

10. PDX MODELS MARKET, BY REGION

  • 10.1. INTRODUCTION
  • 10.2. NORTH AMERICA
    • 10.2.1. US
      • 10.2.1.1. Growing focus on cancer research in the US
      • 10.2.1.2. Rise in mAb production
      • 10.2.1.3. Development of oncology biosimilars boosting the demand for preclinical services
    • 10.2.2. CANADA
      • 10.2.2.1. Rising Stem Cell Research
  • 10.3. EUROPE
    • 10.3.1. FOCUS ON CANCER RESEARCH AND TREATMENT
    • 10.3.2. GERMANY: GROWTH OF THE BIOTECH SECTOR
    • 10.3.3. SPAIN: AVAILABILITY OF VENTURE FUNDING FOR LIFE SCIENCES
    • 10.3.4. ITALY: GROWTH OF THE BIOTECH, PHARMA SECTORS
    • 10.3.5. RISING RESEARCH INVESTMENTS IN SWEDEN, AUSTRIA, AND DENMARK
  • 10.4. ASIA PACIFIC
    • 10.4.1. RISING FOCUS ON PRECISION MEDICINE AND PERSONALIZED MEDICINE IN CHINA
    • 10.4.2. STRONG RESEARCH EXPENDITURE AND WELL-STRUCTURED CROS INDUSTRY IN CHINA
    • 10.4.3. GROWING FOCUS OF PHARMACEUTICAL AND ANIMAL RESEARCH MODEL SUPPLIERS ON CHINA
    • 10.4.4. PUBLIC AND PRIVATE INVESTMENTS IN CHINA'S LIFE SCIENCES SECTOR
    • 10.4.5. INITIATIVES TO REDUCE LONG APPROVAL TIMES IN CHINA
    • 10.4.6. INTELLECTUAL PROPERTY (IP) BREACHES, A CHALLENGE FOR MARKET GROWTH IN CHINA
    • 10.4.7. JAPAN: GROWTH IN BIOMEDICAL AND MEDICAL RESEARCH
    • 10.4.8. INDIA: RISING R&D EXPENDITURE
    • 10.4.9. INFRASTRUCTURAL LIMITATIONS IN INDIA
    • 10.4.10. AVAILABILITY OF FUNDING FOR BIOMEDICAL RESEARCH IN AUSTRALIA
    • 10.4.11. RISING TRANSLATIONAL AND BIOMEDICAL RESEARCH IN SINGAPORE
    • 10.4.12. RISING PHARMACEUTICAL AND BIOTECHNOLOGY R&D IN KOREA
  • 10.5. REST OF THE WORLD (ROW)
    • 10.5.1. RISING R&D IN BRAZIL
    • 10.5.2. GROWTH OF THE PHARMACEUTICAL AND BIOTECHNOLOGY INDUSTRIES IN SAUDI ARABIA AND THE UAE

11. COMPETITIVE LANDSCAPE

  • 11.1. INTRODUCTION
  • 11.2. MARKET RANKING ANALYSIS
  • 11.3. COMPETITIVE LEADERSHIP MAPPING
    • 11.3.1. VISIONARY LEADERS
    • 11.3.2. INNOVATORS
    • 11.3.3. EMERGING COMPANIES
    • 11.3.4. DYNAMIC DIFFERENTIATORS
  • 11.4. COMPETITIVE BENCHMARKING
    • 11.4.1. STRENGTH OF PRODUCT PORTFOLIO
    • 11.4.2. BUSINESS STRATEGY EXCELLENCE

12. COMPANY PROFILES (Overview, Strength of Product Portfolio, Business Strategy Excellence, Products Offering, and Recent Developments)*

  • 12.1. CROWN BIOSCIENCE INC.
  • 12.2. THE JACKSON LABORATORY
  • 12.3. CHAMPIONS ONCOLOGY, INC.
  • 12.4. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
  • 12.5. WUXI APPTEC (GROUP OF SUBSIDIARIES UNDER WUXI PHARMATEC)
  • 12.6. ONCODESIGN
  • 12.7. HORIZON DISCOVERY GROUP PLC (SAGE LABS, INC.)
  • 12.8. PHARMATEST SERVICES LTD.
  • 12.9. HERA BIOLABS
  • 12.10. EPO BERLIN-BUCH GMBH
  • 12.11. XENTECH
  • 12.12. UROLEAD

*Details on Overview, Strength of Product Portfolio, Business Strategy Excellence, Products Offering, and Recent Developments might not be captured in case of unlisted companies.

13. APPENDIX

  • 13.1. DISCUSSION GUIDE
  • 13.2. KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.3. INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
  • 13.4. AVAILABLE CUSTOMIZATIONS
  • 13.5. RELATED REPORTS
  • 13.6. AUTHOR DETAILS

LIST OF TABLES

  • TABLE 1: GLOBAL PDX MODELS MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 2: PDX MICE MODELS MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 3: PDX RAT MODELS MARKET, BY REGION, 2015-2022 (USD THOUSAND)
  • TABLE 4: GLOBAL PDX MODELS MARKET, BY TUMOR TYPE, 2015-2022 (USD MILLION)
  • TABLE 5: GASTROINTESTINAL TUMOR MODELS MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 6: GYNECOLOGICAL TUMOR MODELS MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 7: RESPIRATORY TUMOR MODELS MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 8: UROLOGICAL TUMOR MODELS MARKET, BY REGION, 2015-2022 (USD THOUSAND)
  • TABLE 9: HEMATOLOGICAL TUMOR MODELS MARKET, BY REGION, 2015-2022 (USD THOUSAND)
  • TABLE 10: OTHER TUMOR MODELS MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 11: GLOBAL PDX MODELS MARKET, BY APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 12: PDX MODELS MARKET FOR PRECLINICAL DRUG DEVELOPMENT AND BASIC CANCER RESEARCH, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 13: PDX MODELS MARKET FOR BIOMARKER ANALYSIS, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 14: GLOBAL PDX MODELS MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 15: PDX MODELS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 16: PDX MODELS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 17: PDX MODELS MARKET FOR ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 18: PDX MODELS MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 19: NORTH AMERICA: PDX MODELS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 20: NORTH AMERICA: PDX MODELS MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 21: NORTH AMERICA: PDX MODELS MARKET, BY TUMOR TYPE, 2015-2022 (USD MILLION)
  • TABLE 22: NORTH AMERICA: PDX MODELS MARKET, BY APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 23: NORTH AMERICA: PDX MODELS MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 24: US: PDX MODELS MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 25: US: PDX MODELS MARKET, BY TUMOR TYPE, 2015-2022 (USD MILLION)
  • TABLE 26: US: PDX MODELS MARKET, BY APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 27: US: PDX MODELS MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 28: CANADA: PDX MODELS MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 29: CANADA: PDX MODELS MARKET, BY TUMOR TYPE, 2015-2022 (USD MILLION)
  • TABLE 30: CANADA: PDX MODELS MARKET, BY APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 31: CANADA: PDX MODELS MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 32: EUROPE: PDX MODELS MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 33: EUROPE: PDX MODELS MARKET, BY TUMOR TYPE, 2015-2022 (USD MILLION)
  • TABLE 34: EUROPE: PDX MODELS MARKET, BY APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 35: EUROPE: PDX MODELS MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 36: JAPAN: SIGNIFICANT PARTNERSHIPS
  • TABLE 37: ASIA PACIFIC: PDX MODELS MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 38: ASIA PACIFIC: PDX MODELS MARKET, BY TUMOR TYPE, 2015-2022 (USD MILLION)
  • TABLE 39: ASIA PACIFIC: PDX MODELS MARKET, BY APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 40: ASIA PACIFIC: PDX MODELS MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 41: ROW: PDX MODELS MARKET, BY TYPE, 2015-2022 (USD THOUSAND)
  • TABLE 42: ROW: PDX MODELS MARKET, BY TUMOR TYPE, 2015-2022 (USD THOUSAND)
  • TABLE 43: ROW: PDX MODELS MARKET, BY APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 44: ROW: PDX MODELS MARKET, BY END USER, 2015-2022 (USD MILLION)

LIST OF FIGURES

  • FIGURE 1: GLOBAL PDX MODELS MARKET: RESEARCH METHODOLOGY STEPS
  • FIGURE 2: SAMPLING FRAME: PRIMARY RESEARCH
  • FIGURE 3: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 4: MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH
  • FIGURE 5: MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • FIGURE 6: MARKET FORECAST METHODOLOGY
  • FIGURE 7: DATA TRIANGULATION METHODOLOGY
  • FIGURE 8: GLOBAL PDX MODELS MARKET, BY TYPE (2017)
  • FIGURE 9: GLOBAL PDX MODELS MARKET, BY TUMOR TYPE (2017)
  • FIGURE 10: GLOBAL PDX MODELS MARKET, BY APPLICATION
  • FIGURE 11: GLOBAL PDX MODELS MARKET, BY END USER
  • FIGURE 12: ASIA PACIFIC TO WITNESS HIGHEST GROWTH DURING THE FORECAST PERIOD
  • FIGURE 13: GROWING CANCER RESEARCH TO DRIVE THE GLOBAL PDX MODELS MARKET
  • FIGURE 14: NORTH AMERICA IS EXPECTED TO DOMINATE THE PDX MODELS MARKET IN 2017
  • FIGURE 15: GASTROINTESTINAL TUMORS TO ACCOUNT FOR THE LARGEST SHARE OF THE MARKET IN 2017
  • FIGURE 16: THE ASIA PACIFIC REGION TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
  • FIGURE 17: PDX MODELS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 18: MICE MODELS TO DOMINATE THE PDX MODELS MARKET DURING THE FORECAST PERIOD
  • FIGURE 19: GASTROINTESTINAL TUMOR MODELS IS EXPECTED TO ACCOUNT FOR THE LARGEST MARKET SHARE IN 2017
  • FIGURE 20: PRECLINICAL DRUG DEVELOPMENT AND BASIC CANCER RESEARCH APPLICATIONS TO DOMINATE THE PDX MODELS MARKET
  • FIGURE 21: CONTRACT RESEARCH ORGANIZATIONS TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD
  • FIGURE 22: ASIA PACIFIC TO GROW AT THE HIGHEST CAGR IN THE PDX MODELS MARKET
  • FIGURE 23: NORTH AMERICA: PDX MODELS MARKET SNAPSHOT
  • FIGURE 24: EUROPE: PDX MODELS MARKET SNAPSHOT
  • FIGURE 25: ASIA PACIFIC: PDX MODELS MARKET SNAPSHOT
  • FIGURE 26: ROW: PDX MODELS MARKET SNAPSHOT
  • FIGURE 27: GLOBAL PDX MODEL MARKET RANKING (AS OF 2016)
  • FIGURE 28: PDX MODELS MARKET (GLOBAL) COMPETITIVE LEADERSHIP MAPPING, 2017
  • FIGURE 29: THE JACKSON LABORATORY: COMPANY SNAPSHOT (2016)
  • FIGURE 30: CHAMPIONS ONCOLOGY, INC.: COMPANY SNAPSHOT (2016)
  • FIGURE 31: CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: COMPANY SNAPSHOT (2016)
  • FIGURE 32: WUXI PHARMATEC: COMPANY SNAPSHOT (2015)
  • FIGURE 33: ONCODESIGN: COMPANY SNAPSHOT (2016)
  • FIGURE 34: HORIZON DISCOVERY GROUP PLC: COMPANY SNAPSHOT (2016)
Back to Top